- Home
- ELA vs IPHA Comparison
ELA vs IPHA Comparison
Compare ELA & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELA
- IPHA
- Stock Information
- Founded
- ELA 1965
- IPHA 1999
- Country
- ELA United States
- IPHA France
- Employees
- ELA N/A
- IPHA N/A
- Industry
- ELA Consumer Specialties
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- ELA Consumer Discretionary
- IPHA Health Care
- Exchange
- ELA Nasdaq
- IPHA Nasdaq
- Market Cap
- ELA 173.1M
- IPHA 150.9M
- IPO Year
- ELA N/A
- IPHA 2019
- Fundamental
- Price
- ELA $6.75
- IPHA $1.95
- Analyst Decision
- ELA Strong Buy
- IPHA Strong Buy
- Analyst Count
- ELA 1
- IPHA 1
- Target Price
- ELA $7.00
- IPHA $11.50
- AVG Volume (30 Days)
- ELA 17.3K
- IPHA 50.9K
- Earning Date
- ELA 03-19-2025
- IPHA 03-20-2025
- Dividend Yield
- ELA N/A
- IPHA N/A
- EPS Growth
- ELA N/A
- IPHA N/A
- EPS
- ELA 0.25
- IPHA N/A
- Revenue
- ELA $165,946,534.00
- IPHA $36,202,722.00
- Revenue This Year
- ELA $1.61
- IPHA N/A
- Revenue Next Year
- ELA $6.30
- IPHA $101.65
- P/E Ratio
- ELA $27.13
- IPHA N/A
- Revenue Growth
- ELA N/A
- IPHA N/A
- 52 Week Low
- ELA $4.20
- IPHA $1.29
- 52 Week High
- ELA $7.88
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- ELA 42.74
- IPHA 56.50
- Support Level
- ELA $6.04
- IPHA $1.72
- Resistance Level
- ELA $7.05
- IPHA $1.92
- Average True Range (ATR)
- ELA 0.34
- IPHA 0.10
- MACD
- ELA -0.06
- IPHA 0.02
- Stochastic Oscillator
- ELA 48.63
- IPHA 100.00
About ELA Envela Corporation
Envela Corp and its subsidiaries engage in diverse business activities within the recommerce sector. These include re-commercializing luxury hard assets, consumer electronics and IT equipment; and end-of-life recycling solutions. It operates through two segments, Consumer, and Commercial Services. The Consumer segment which generates key revenue for the company predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.